A phase 3 trial of AstraZeneca’s $800 million rare disease candidate has met its primary endpoint. The update keeps ...
Imfinzi has been approved in the European Union as monotherapy for the treatment of adults with limited-stage small cell ...
CAMBRIDGE, UK] Drugmaker AstraZeneca said on Monday (Mar 17) it will buy biotechnology firm EsoBiotec for up to US$1 billion.
Phoenix shares surge on upgraded guidance 08:26 , Graeme Evans The FTSE 100-listed shares of ...
AstraZeneca (AZN) and Alteogen have entered into an exclusive license agreement for ALT-B4, a novel hyaluronidase utilising Hybrozyme platform ...
AstraZeneca is hopping aboard the pickleball craze as its serves up a new marketing push for its asthma med Fasenra. | ...
3d
Investor's Business Daily on MSNAstraZeneca Stock Nears Buy Point After Long Run In Declining MarketAstraZeneca is Thursday's pick for IBD 50 Growth Stocks To Watch as the biopharmaceutical name is holding up relatively well ...
2d
Pharmaceutical Technology on MSNAstraZeneca director says AI must be a “thought partner” in drug discoveryAstraZeneca’s senior director in oncology data science outlined how the company uses AI for drug discovery at a recent talk.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results